Ann Rheum Dis: Maintenance of clinical remission after early axial spinal arthritis permeable sheadmono resistance

The best strategy for maintaining clinical remission in patients with mid-axis spinal arthritis (axSpA) is uncertainC-OPTIMISE compared the outcome of the original dose, reduction and discontinuation of the tumor necrosis inhibitor persitizing the metastaizing monoblast (CZP) of tumor necrosis factor after the early axSpA patients reached continuous remissionC-OPTIMISE is a two-part, multicenter 3b phase 3b study of early active axSpA (radiology or non-radiology) adult patientsDuring 48 weeks of open label induction, patients receive 200mg CZP every 2 weeks (Q2W)At week 48, patients with continuous remission (strong scoliosis activity score (ASDAS) 1.3) were randomly classified as bi-blind CZP 200mg Q2W (maintenance dose group) every 4 weeks 0 mg (Q4W; reduced group) or placebo (discontinued group) for another 48 weeksThe main endpoint is to maintain no acute seizures during double blindness (acute seizures: ASDAS 2.1 or any point in time asas asas 3.5)week 48, 43.9% of patients (323/736) achieved sustained remission, of which 313 were randomly assigned to the CZP maintenance dose group, the CZP reduction group, or the placebo groupBetween 48 and 96 weeks, 83.7% (87/104), 79.0% (83/105) and 20.2% (21/104) were patients with no acute seizures in the maintenance dose group, the reduced group, or the placebo group (two CZP groups vsplacebo group, p 0.001), respectivelyThe response of patients with radiology and non-radiology axSpA was comparablein patients with an early axSpA that achieves continuous remission at 48 weeks can reduce the maintenance dose of CZP;